CEO and Board Replacement

While FDA approval is important, experienced and qualified leadership in medicine or medical devices is crucial.

UBI needs strong leadership who works for all shareholders not just selected few. A Credit raise notification issued just a week before FDA decision and even after the favourable decision management went ahead and sold company shares to heavily discounted price only to the selected few individuals.

Perhaps investors should consider calling for a board shakeup, with a focus on replacing the CEO and Chairman.

Additionally, the recent large share sale (24 million on the 19th) may be clarified by next week's substantial holder notice. It's important to see if this was a simple selling for profit by few individuals or someone dumping only to make CR price looks good.

I've already filed complaints with ASIC and ASX regarding this situation. Instead of just discussing it online, perhaps others should consider doing the same. A regulatory investigation into the recent stock dump and significantly discounted credit raise after FDA approval might be warranted.